Keftragard 1000mg/500mg Injection is a sterile, injectable formulation combining Ceftriaxone, a third-generation cephalosporin antibiotic (1000mg), with Sulbactam, a beta-lactamase inhibitor (500mg). This combination enhances the antibacterial spectrum of Ceftriaxone by inhibiting beta-lactamase enzymes produced by resistant bacteria, thereby restoring its efficacy against beta-lactamase-producing pathogens. Keftragard is indicated for the treatment of a wide range of infections caused by susceptible organisms, including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, bone and joint infections, and septicemia. The drug exhibits bactericidal activity by interfering with bacterial cell wall synthesis, leading to cell lysis and death. Ceftriaxone’s long half-life allows once-daily dosing, while Sulbactam’s presence broadens coverage against resistant strains. Administration is via intravenous or intramuscular injection, with dosage and duration tailored according to infection severity, site, and patient factors such as renal function. Common adverse effects may include local injection site reactions, gastrointestinal disturbances, and hypersensitivity reactions. Caution is advised in patients with penicillin allergy or hepatic impairment. Keftragard should be used under strict medical supervision to ensure appropriate use and minimize resistance development.